Trastuzumab biosimilar (Pfizer)

曲妥珠单抗生物类似药（辉瑞）

Report date: 2023/04/23 15:30:19

Base Information

Drug NameTrastuzumab biosimilar (Pfizer)
Drug Alias Name曲妥珠单抗生物仿制药（辉瑞）Trazimeratrastuzumab-qyypPF-5280014PF-05280014
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonists
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsMetastatic breast cancerSolid tumoursUrinary Bladder Neoplasms +[28] 
Global Approved IndicationsStomach NeoplasmsBreast Neoplasms
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2018/07/26
Country/TerritoryCzechiaBelgiumUnited States +[32] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesSeagen IncPfizer IncNational Cancer Institute +[4] 
Inactive CompaniesN/A
Active IndicationsSolid tumoursUrinary Bladder NeoplasmsProstatic Neoplasms +[27] 
Inactive IndicationsMetastatic breast cancer

Other Information

ATC CodeL01XC03
Related LinksN/A